Samsung Biologics Signs 381 Billion KRW Contract for Pharmaceutical Contract Manufacturing with European Pharma Company
[Asia Economy Reporter Park Jihwan] Samsung Biologics announced on the 24th that it has signed a letter of intent for a contract to manufacture biopharmaceuticals on consignment worth 381 billion KRW with a European pharmaceutical company.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This corresponds to 54.30% of last year's sales revenue.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
